Moods Disorders Completed Phase 1 Trials for Reboxetine (DB00234)

Also known as: Mood Disorders / Mood Disorder

IndicationStatusPhase
DBCOND0058256 (Moods Disorders)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00886886Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)Basic Science